针对神经退行性疾病中伴侣介导的自:机制和治疗潜力
1Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Center of Soochow University, Suzhou, 215123, China. jinw913@163.com.
Acta pharmacologica Sinica
|November 15, 2024
概括
伴奏介导自 (CMA) 降解了与神经退行性疾病 (如帕金森病和阿尔茨海默病) 相关的错误折叠蛋白质. 激活CMA通过管理蛋白质积聚和神经炎症,显示出对这些疾病的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 免疫学 免疫学 免疫学
背景情况:
- 神经退行性疾病的特征是错误折叠的蛋白质聚合和神经炎症.
- 伴奏介导自 (CMA) 是通过 lysosomes 降解特定蛋白质的关键途径.
- CMA识别了具有KFERQ图案的蛋白质,这是HSC70.0的目标.
研究的目的:
- 审查CMA的分子机制和调节.
- 探索CMA在神经元蛋白质稳定和质介导的神经炎症中的作用.
- 总结CMA调制器在治疗干预方面的进展.
主要方法:
- 对CMA的分子机制和调节途径的文献综述.
- 分析CMA在神经元蛋白质质量控制中的功能.
- 对CMA调节器及其治疗影响的当前研究的综合.
主要成果:
- CMA对于特定的错误折叠蛋白质的溶酶体降解至关重要.
- CMA在调节涉及质细胞的神经炎症方面发挥着重要作用.
- 新兴的CMA调节器为神经退行性疾病提供了潜在的治疗策略.
结论:
- 激活CMA是神经退行性疾病的一种有前途的治疗方法.
- 准CMA可以解决蛋白质聚合和神经炎症.
- 对CMA调节器的进一步研究有必要进行临床应用.
相关概念视频
Autophagy
4.2K
Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
Delivery Pathways to the Lysosome
6.2K
Eukaryotic cells use different mechanisms to eliminate toxic waste obsolete and worn-out substances. Lysosomes play a pivotal role in this, and hence, these substances are carried to the lysosome from other parts of the cell and extracellular space through different pathways. The most elaborately studied pathways to the lysosome are the endocytic pathways.
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
6.2K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Autophagic Cell Death
3.4K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.4K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Parkinson's Disease: Overview
482
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
482


